Oculis Holding AG (OCS), a clinical-stage biopharmaceutical, announced on Monday the completion of the final patient visit in the Phase 3 DIAMOND program of OCS-01,it's lead investigational eye drop in diabetic macular edema or DME. Oculis expects to report topline results in June 2026.
OCS-01 is a high-concentration dexamethasone eye drop formulation developed to treat the retina for diabetic macular oedema. The DIAMOND program consists of two Phase 3 trials named DIAMOND-1 and DIAMOND-2, randomised, double-masked, multicenter studies evaluating the efficacy and safety of OCS-01 over 52 weeks.
Oculis enrolled over 800 patients across both pivotal trials, who were randomised 1:1 to receive OCS-01 or vehicle administered six times daily during a 6-week induction phase, followed by three times daily dosing through week 52.
The firm estimated 1 million patients out of the 1.8 million people diagnosed with DME in the U.S. remain untreated or underserved.
Beyond OCS-01, Oculis' late-stage pipeline includes Privosegtor (OCS-05) in the PIONEER program for optic neuropathies such as optic neuritis and non-arteritic anterior ischemic optic neuropathy or NAION, and Licaminlimab in a registrational trial for dry eye disease.
As of December 31, the firm had cash, cash equivalents, and short-term investments of $268.7 million and expects a cash runway into 2029.
OCS has traded between $16 and $30.68 over the last year. The stock closed Friday's trade at $27.46, up 0.33%.
For More Such Biotech Stock News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.